Recently,Pan-vascular Active Interventional EnterprisesSonosemi Medical Co., Ltd. (hereinafter referred to as "SONOSEMI")Completion AnnouncedHundreds of Millions in Series B+ Funding。
This round of financing is led byYahui Investment、Sidao CapitalCo-lead investor,Furong InvestmentExisting shareholders will continue to participate in follow-on investments. The funds raised will be primarily allocated to the R&D and regulatory registration of core product pipelines, the establishment of supply chain and commercialization channels, as well as clinical and academic promotion.
This marks another multi-hundred-million-yuan financing round for SONOSEMI, following its completion of a Series B funding round exceeding RMB 200 million in 2023.
When SONOSEMI completed its Series B financing in 2023, several of its core products were still in the registration application or pre-launch stages. At that time, the company characterized this round of financing as occurring on the eve of product commercialization. Its publicly disclosed pipeline already covered areas such as intracoronary shockwave therapy, peripheral intravascular shockwave therapy, intracardiac echocardiography (ICE), and intravascular ultrasound (IVUS); however, most of these products had not yet entered the market.
Three years later, SONOSEMI has transitioned from having multiple pipelines under development to the commercialization phase following the centralized approval of several products.
# Multiple Product Lines Successfully Registered in SequenceSONOSEMI, established in 2020, focuses on active interventional diagnosis and treatment products for vascular diseases, with a product portfolio covering coronary intervention, peripheral intervention, structural heart disease, and cardiac electrophysiology.The company's first core product line is intravascular shockwave.▲Coronary Intravascular Shockwave Therapy System2023, SONOSEMICoronary Intravascular Shockwave Therapy SystemApproved for market launch by the NMPA. Subsequently, its peripheral intravascular shockwave therapy system also completed registration, further extending its application scenarios from coronary calcified lesions to peripheral vascular calcified lesions. According to the company’s publicly disclosed development history, both the peripheral shockwave therapy system and the intracardiac echocardiography (ICE) imaging system were approved in 2024.The second main line is interventional ultrasound.In July 2024, SONOSEMI’s single-use intracardiac echocardiography imaging catheter received approval from the National Medical Products Administration (NMPA) and was launched in accordance with the special review procedure for innovative medical devices.▲Intracardiac Echocardiography Imaging System (ICE)In 2025, the Company’s intravascular ultrasound (IVUS) diagnostic equipment and coronary IVUS diagnostic catheters received successive regulatory approvals, further establishing a multimodal ultrasound diagnostic platform compatible with intracardiac echocardiography (ICE) catheters, coronary IVUS catheters, and external ultrasound transducers.In January 2026, SONOSEMI's coronary scoring balloon dilation catheter was also launched.To date, the company’s publicly available products cover multiple interventional procedures, including the management of calcified lesions, lesion predilation, intracardiac imaging, and intravascular coronary imaging.This also means that the logic behind this round of financing differs from that of the previous round.The previous round of financing primarily supported product R&D, clinical trials, and regulatory registration; this round of funding is clearly tilted towards supply chain development, channel establishment, and clinical promotion. For SONOSEMI, the upcoming challenge is no longer just obtaining more regulatory approvals, but rather how to simultaneously drive multiple products into hospitals and establish their stable adoption.To date, SONOSEMI's financing history is as follows:Comprehensive Solutions for All Cardiovascular Conditions
